| Title |
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy
|
|---|---|
| Published in |
High Blood Pressure & Cardiovascular Prevention, March 2018
|
| DOI | 10.1007/s40292-018-0256-1 |
| Pubmed ID | |
| Authors |
Andrea Iannaccone, G. Bruno, A. Ravera, F. Gay, M. Salvini, S. Bringhen, L. Sabia, E. Avenatti, F. Veglio, A. Milan |
| Abstract |
Recently new treatment options have substantially increased survival for patients with relapsed and/or refractory multiple myeloma (RRMM). Among these, proteasome inhibitors (PI), such as bortezomib and carfilzomib, offer high response rate and prolonged survival. These agents are generally well tolerated but demonstrated a significant cardiovascular toxicity, mostly for regimen containing carfilzomib. To assess the cardiovascular damage in patients treated with PI for RRMM. 28 consecutive subjects treated with PI for RRMM were evaluated and compared with a population of 22 control (Con) subjects, matched for age, sex and mean 24 h blood pressure (24hMBP). All individuals underwent trans-thoracic echocardiography, ambulatory blood pressure monitoring and pulse wave velocity (PVW) study. PI patients did not have significant differences in blood pressure load and PWV compared to controls. Among echocardiographic parameters, the global longitudinal strain (GLS) was significantly decreased in PI subjects (p = 0.02). The GLS was significantly lower also considering only patients treated with carfilzomib. Moreover, among carfilzomib patients, we found increase values of left ventricle mass indexed by BSA (LVMi; p = 0.047). After correction for age, sex, BSA, 24hMBP and morphological and functional parameters of LV, treatment with PI and carfilzomib were significantly associated with GLS (p = 0.01; p = 0.036, respectively). PI treatment is associated with subclinical LV dysfunction in patients with RRMM compared to controls, as demonstrated by lower GLS values. These results are confirmed also considering patients treated with carfilzomib. Moreover, in this subgroup of patients, the LVMi is also increased, suggesting higher cardiotoxicity with this treatment. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 18% |
| Other | 5 | 13% |
| Student > Bachelor | 4 | 10% |
| Student > Master | 4 | 10% |
| Student > Ph. D. Student | 3 | 8% |
| Other | 5 | 13% |
| Unknown | 12 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 40% |
| Biochemistry, Genetics and Molecular Biology | 3 | 8% |
| Psychology | 2 | 5% |
| Engineering | 2 | 5% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 4 | 10% |
| Unknown | 12 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2020.
All research outputs
#6,872,724
of 23,031,582 outputs
Outputs from High Blood Pressure & Cardiovascular Prevention
#46
of 248 outputs
Outputs of similar age
#119,774
of 330,380 outputs
Outputs of similar age from High Blood Pressure & Cardiovascular Prevention
#1
of 7 outputs
Altmetric has tracked 23,031,582 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 248 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,380 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them